Pharmaxis Releases Promising Interim Data from Skin Scarring Study
Release Date: 26/09/2022 10:00am
Pharmaxis has released promising interim data from the clinical trial of its topical anti scarring drug PXS-6302 being conducted by the University of Western Australia (UWA) under the leadership of Professor Fiona Wood AM. The study aims to improve the appearance and function of established scars by tackling the enzyme that plays a critical role in crosslinking collagen fibres in scar formation.
Watch an interview with CEO Gary Phillips outlining the study data here.
Watch the Channel Nine News story here
Watch the online investor briefing by chief executive officer Mr Gary Phillips on September 26 2022 here.
Categories: Video Content